Table 4 GEE models for the impact of clinical factors on the final BCVA after treatment.

From: Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases

 

All subjects

Responder group

Non-responder group

B (S.E.)

P value

B (S.E.)

P value

B (S.E.)

P value

Age (years)

0.016 (0.005)

0.001*

0.002 (0.004)

0.555

0.008 (0.005)

0.070

HbA1c (%)

0.057 (0.033)

0.085

0.060 (0.024)

0.013*

−0.019 (0.027)

0.481

Baseline BCVA (LogMAR)

0.478 (0.228)

0.036*

0.343 (0.301)

0.254

0.745 (0.233)

0.001*

Baseline CST (μm)

0.002 (0.001)

0.062

0.002 (0.001)

0.019*

0.002 (0.001)

0.002*

PDR

−0.005 (0.098)

0.962

−0.083 (0.067)

0.217

0.144 (0.061)

0.019*

No of IVI

0.070 (0.033)

0.035*

0.061 (0.032)

0.055

0.016 (0.020)

0.401

  1. B (S.E.): regression coefficient (standard error), BCVA: best corrected visual acuity, CST: central subfield thickness, HbA1C: glycosylated hemoglobin, IVI: intravitreal injection, PDR: Proliferative diabetic retinopathy, *P < 0.05.
Back to article page